Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.39 |
| ▸ | ESRRA | P11474 | 7/20 | 0.37 |
| ▸ | ESRRB | O95718 | 6/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384472 | 1.00 | ESR1 (0.39) | ESR1ESR2ESRRAESRRBAR | |
| SCHEMBL3840410 | 0.86 | ESR1 (0.41) | ESR1ESR2ESRRAESRRBAR | |
| SCHEMBL4455896 | 0.81 | ESR1 (0.34) | ESR1ESR2ESRRAESRRBAR | |
| SCHEMBL4450109 | 0.80 | ESR1 (0.43) | ESR1ESR2ESRRAESRRBAR | |
| SCHEMBL3190668 | 0.74 | ESRRB (0.44) | ESR1ESR2ESRRAESRRBAR | |
| SCHEMBL14105587 | 0.73 | ESRRB (0.37) | ESR1ESR2ESRRAESRRB | |
| SCHEMBL4454413 | 0.72 | ESR1 (0.48) | ESR1ESR2ESRRAESRRBAR | |
| SCHEMBL3201595 | 0.69 | ESRRB (0.49) | ESR1ESR2ESRRAESRRBCHEK1 | |
| SCHEMBL4448363 | 0.69 | ESR1 (0.37) | ESR1ESR2ESRRAESRRB | |
| SCHEMBL3923874 | 0.69 | ESR1 (0.40) | ESR1ESR2ESRRAESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035855-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-11 | — | — | US | claimed |
| US-20100092463-A1 | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-04-15 | — | — | US | disclosed |
| US-20100061976-A1 | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-03-11 | — | — | US | disclosed |
| US-20100035855-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-11 | — | — | US | disclosed |
| US-20100022497-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |